IRVINE, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, and Sync Health Solutions, innovators of products and companies within the health and wellness industry, announced the launch of Sync Health Solutions' new branded lifestyle energy product, Älsa™. The energy burst from Älsa™ is derived from ChromaDex's patented PURENERGY®.
By dissolving a single-dose Älsa packet in 16 ounces of water, the vegan and gluten-free powder solution provides active adults a healthy, sustained energy lift without the jolt typical in highly-caffeinated energy products.
PURENERGY® is a unique co-crystal combination of caffeine and ChromaDex's patented pTeroPure® pterostilbene that produces superior benefits as compared to caffeine alone. A clinical study showed that 30% more caffeine was delivered into the blood than ordinary caffeine and the half-life was extended by nearly 25%. This data indicates there is a sustained energy boost for at least six hours and there is a potential for a more moderate and gradual finish.
Thaddeus "Thad" Hyland, co-Founder of Älsa, stated: "We believe there is significant demand from busy, active adults seeking a healthy daily energy product that is not highly caffeinated, like other energy drinks. The unique attributes of PURENERGY® makes Älsa such a product. By delivering energy faster and longer than traditional highly caffeinated products, Älsa will give active adults the extra boost and mental focus they need to get through their busy days, without the caffeine crash."
Frank Jaksch Jr., founder and CEO of ChromaDex, commented, "We are extremely excited to have our PURENERGY® as a main ingredient in Älsa. PURENERGY® out performs ordinary caffeine by 30% while at the same time providing all the benefits of an antioxidant. We believe energy products looking to be differentiated from highly caffeinated alternatives is an outstanding application for PURENERGY®."
About Sync Health Solutions:
Sync Health Solutions LLC develops products and companies in the health and wellness industry. Its initiatives focus on direct to consumer opportunities made available through its affiliation with Landmark Global and Vantage Group. Operational support, logistics, supply chain management, branding, and marketing are shared resources that maximize efficiencies across its platform. To learn more about Älsa and Sync Health Solutions, please visit www.synchealthsolutions.com.
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; ProC3G®, a natural black rice containing cyanidin-3-glucoside; and Suntava® Purple Corn derived from a proprietary non-GMO purple corn hybrid which contains an extraordinarily high level of anthocyanins. To learn more about ChromaDex, please visit www.ChromaDex.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in ChromaDex's business. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended January 3, 2015, ChromaDex's Quarter Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
CONTACT: ChromaDex Company Contact: Andrew Johnson, Director of Investor Relations 949-419-0288 firstname.lastname@example.org ChromaDex Investor Contacts: The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 email@example.com